AI assistant
CAMBIUM BIO LIMITED — M&A Activity 2024
Mar 27, 2024
64666_rns_2024-03-27_260e2c44-52c8-44c2-854f-7923ce5382e1.pdf
M&A Activity
Open in viewerOpens in your device viewer
==> picture [144 x 30] intentionally omitted <==
ASX Announcement
28 March 2024
Regeneus secures shareholder approval for merger with Cambium Medical Technologies LLC
Sydney, Australia; 28 March 2024: Regeneus Ltd (ASX:RGS) ( Regeneus or Company ), a clinical-stage regenerative medicine company, has today secured shareholder approval for the proposed merger with Cambium Medical Technologies, LLC ( CMT ).
Details of the merger were disclosed in Regeneus’ announcement to the ASX made on 14 February 2024 and details about the CMT business are set out in the Shareholder Update presentation to the ASX made on 28 September 2023.
Regeneus is currently working to finalise the last of the conditions to closing occuring pursuant to the merger agreement. It is expected that these conditions will be satisfied in the coming days.
The merger will then be formally affected by lodgement of the Articles of Merger in Georgia USA.
Regeneus expects to be in a position to update the market in the coming week.
- ENDS -
About Cambium Bio Limited
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company utilizing stem cell technologies to develop a portfolio of novel cell-based therapies. The Company's regenerative platform technologies, Progenza™ and Sygenus, aim to address unmet medical needs in human health markets, focusing on neuropathic pain, osteoarthritis, and various skin conditions. For more information, please visit www.regeneus.com.au.
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Regeneus Ltd.
16 Goodhope Street, Paddington, NSW 2021 Ph: 1 300 995 098 • www.regeneus.com.au • ABN 13 127 035 358